Article
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
Oncotarget - 26 Apr 2016
Wen Yihui, Li Hua, Zeng Yan, Wen Weiping, Pendleton Kelsey P, Lui Vivian W Y, Egloff Ann Marie, Grandis Jennifer R
Abstract excerpt
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have not been effective in unselected head and neck squamous cell carcinoma (HNSCC) populations. We previously reported an exceptional response to a brief course of erlotinib in a patient with advanced HNSCC whose tumor harbored a MAPK1E322K somatic mutation. MAPK1E322Kwas associated with increased p-EGFR, increased EGFR downstream...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.